Dr Stanley Frankel
Dr. Frankel is Corporate Vice President, Head of Immuno-oncology, Clinical Research and Development at Celgene. His current research focus includes checkpoint inhibitors and cellular therapies.
Through 2014 he served as Executive Director, Medical Sciences; Early Development, Oncology Therapeutic Area Head at Amgen. Among his primary responsibilities at Amgen were the clinical development of bispecific T cell engaging antibody constructs (BiTE®s) inclucing blinatumomab, immune-oncology agents, antibody drug conjugates, and small molecules directed at anti-apoptotic proteins. He joined Amgen following the acquisition of Micromet where he served as Vice President, Clinical Develoment.
Prior experience includes roles as Clinical Director and Clinical Science Leader at Hoffman-LaRoche; Executive Director for US External Scientific Affairs and Senior Director, Clinical Research at Merck. Dr. Frankel chaired the Zolinza Product Development Team and led the clinical efforts for the successful approval of Zolinza in 2006. From 2001-2004, he was Director, Medical Operations, at Genta, Inc working on Genasense.
Prior to joining Genta, Dr. Frankel was Clinical Associate Professor of Medicine at the University of Maryland in Baltimore Greenebaum Cancer Center. He was previously on the faculty at Roswell Park Cancer Institute in Buffalo, NY and the Lombardi Cancer Center at Georgetown University.
Dr. Frankel received his B.A. from Harvard College and his M.D. from Northwestern University. He received his post-graduate training at Mount Sinai Hospital in New York, and Memorial Sloan-Kettering Cancer Center where he was Chief Fellow.
In addition to his contributions to the approval of Blincyto and Zolinza, Dr. Frankel worked as an academic investigator on the development of 11 other approved oncology drugs including Vesanoid and Trisenox for acute promyelocytic leukemia, Rituxan, Zevalin, Bexxar for CD20 expressing malignancies, Neulasta, Kepivance, Mylotarg, and Gleevec. Dr. Frankel has internationally recognized clinical expertise in the treatment of hematologic malignancies including ALL and lymphoma.
Dr. Frankel is a Diplomate of the American Board of Internal Medicine with subspecialty credentials in Hematology and Medical Oncology. He is also an Adjunct Associate Professor of Medicine at Columbia College of Physicians and Surgeons.
He is a Fellow of the American College of Physicians. He is a member of AACR, ASBMT, ASCO, ASH, EHA, and ESMO. He has authored more than 80 peer-reviewed scientific papers.